Nice, France, May 1, 2019 - Uveitis is an intraocular inflammation that partly or totally affects the iris, ciliary body and choroid, the causes of which are not always known and may be varied: ocular trauma or systemic diseases of genetic, immune or infectious origin. Uveitis can be acute or chronic. During chronic uveitis, the untreated and prolongated inflammation can spread and affect other ocular structures, such as the lens, vitreous gel, retina or optic nerve, leading to cataracts, glaucoma or macular edema, which leads to loss of vision.
Iris Pharma’s highly skilled and experienced staff has validated a new model of chronic uveitis, with the anatomic site of inflammation affecting both anterior and posterior segments of the eye. This experimental model of panuveitis was induced by the Mycobacterium tuberculosis H37Ra antigen in preimmunized rabbits.
ARVO meeting 2019; Vancouver - CANADA. Abstract No. 800 - B0278
" Chronic model of uveitis in rabbit - Efficacy of Triamcinolone Acetonide"
About Iris Pharma:
Iris Pharma is an independent CRO specializing in preclinical and clinical research services in ophthalmology. Founded in 1989 by Dr Pierre-Paul Elena, Iris Pharma offers expertise in the development of ophthalmic drugs and ocular medical devices to the pharmaceutical industry and biotechnology companies worldwide. Iris Pharma services include proof of concept and GLP-compliant preclinical studies (safety, tolerance, pharmacokinetics, efficacy), bioanalysis, preclinical formulation, clinical trials and consulting services. Iris Pharma’s research facilities are GLP compliant.